News

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels. 

Press Releases
BIO Applauds Introduction of Bipartisan…
BIO President and CEO John F. Crowley today released the following statement after a bipartisan group of Senators, Sen. Bob Casey (D-PA), Sen. Markwayne Mullin (R-OK), Sen. Sherrod Brown (D-OH), and Sen. Susan Collins (R-ME), introduced the Creating…
BIO International Convention Celebrates Another…
Biotechnology Innovation Organization (BIO) is proud to conclude the 2024 BIO International Convention in San Diego, held last week June 3-6, 2024. 1,400 exhibitors and more than 19,500 attendees from 70 countries came together for four full days of…
BIO Recognizes Industry Leaders for…
WASHINGTON - June 5, 2024 – The Biotechnology Innovation Organization (BIO) today announced the winners of the organization’s 2024 Leadership in Agri-Biotechnology Awards — honoring Dr. Annette Kleiser, CEO of Dalan Animal Health, as the recipient…
Letters, Testimony, & Comments
Comments of the Biotechnology Innovation…
On behalf of its member organizations, Biotechnology Innovation Organization (“BIO”) respectfully submits this Comment in response to the United States Patent and Trademark Office’s (the “Patent Office” or “PTO”) February 13, 2024 Request for…
BIO Comments to FWS on Use of GMOs on National…
BIO comments on a proposed rule to restrict planting of GE organisms on national wildlife refuge lands. 
BIO Comments to the Minnesota Department of…
BIO submits comments on the MDH’s proposed regulations regarding Drugs of Substantial Public Interest: Draft Methodology for Public Comment as required in statute by the Prescription Drug Price Transparency Act.    
Amicus Briefs
BIO FILES AMICUS BRIEF CHALLENGING FTC’S…
The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge the Federal Trade Commission (FTC) lawsuit to block the acquisition of Horizon by Amgen. The amicus brief was filed in the U.S. District Court, Northern…
BIO Files Amicus Brief in U.S. ex rel. Scutte v…
BIO has filed an amicus brief in U.S. ex rel. Scutte v. SuperValu Inc., which addresses the issue of the intent requirement under the False Claims Act (FCA). Specifically, BIO urges the Court to uphold the view that a firm does not…
BIO JOINS AMICUS BRIEF CHALLENGING COURT’S…
The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge a District Court’s unprecedented ruling (related to a single drug known as mifepristone) that would create regulatory barriers and potentially upend FDA’s…